Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 9—September 2015
THEME ISSUE
Emerging Infections Program
Emerging Infections Program

Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008–2012

Susan HaririComments to Author , Lauri E. Markowitz, Nancy M. Bennett, Linda Niccolai, Sean D. Schafer, Karen C. Bloch, Ina U. Park, Mary W. Scahill, Pamela Julian, Nasreen Abdullah, Diane Levine, Erin Whitney, Elizabeth R. Unger, Martin Steinau, Heidi M. Bauer, James I. Meek, James L. Hadler, Lynn Sosa, Suzanne E. Powell, Michelle L. Johnson, and HPV-IMPACT Working Group1
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S. Hariri, L.E. Markowitz, E.R. Unger, M. Steinau, S.E. Powell, M.L. Johnson); University of Rochester School of Medicine and Dentistry, Rochester, New York, USA (N.M. Bennett, M.W. Scahill); Yale School of Public Health, New Haven, Connecticut, USA (L.M. Niccolai, P. Julian, J. Meek, J. Hadler); Oregon Health Authority, Portland, Oregon, USA (S. Schafer, N. Abdullah); Vanderbilt University School of Medicine, Nashville, Tennessee, USA (K. Bloch, D. Levine); California Department of Public Health, Richmond, California, USA (I.U. Park, E. Whitney, H.M. Bauer); Connecticut Department of Health, Hartford, Connecticut, USA (L. Sosa)

Main Article

Table

Selected characteristics among women with a diagnosis of CIN2+, Emerging Infections Program HPV-IMPACT project, United States, 2008–2012*

Characteristic No. (%)
Diagnosis age, y, N = 13,089
18–20 507 (4)
21–29 6,294 (48)
30–39 3,774 (29)
40–49 1,575 (12)
>50
 939 (7)
Race/ethnicity, N = 10,932
White, non-Hispanic 6,629 (61)
Black, non-Hispanic 1,857 (17)
Hispanic 1,540 (14)
Asian 551 (5)
Other 355 (3)
Missing
 2,157
Vaccination status, N = 7,344
Vaccinated 1,811 (25)
Not vaccinated 1,812 (25)
Unknown 3,721 (51)
Not age-eligible
 5,745
Diagnosis, N = 13,089
CIN2 6,275 (48)
CIN2/3 2,149 (16)
CIN3/AIS
 4,665 (36)
Site location, N = 13,089
California 2,286 (17)
Connecticut 3,729 (28)
New York 2,813 (21)
Oregon 2,557 (20)
Tennessee 1,704 (13)

*AIS, adenocarcinoma in situ; CIN, cervical intraepithelial neoplasia; CIN+, CIN grade 2 or 3 or adenocarcinoma in situ; HPV, human papillomavirus.

Main Article

1Members of the Working Group are Ashley Williamson, Manideepthi Pemmaraju, Robert S. Laing III, Deven Patel, and Kyle Higgins.

Page created: August 12, 2015
Page updated: August 12, 2015
Page reviewed: August 12, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external